Zejula, known generically as niraparib, received its initial U.S. Food and Drug Administration (FDA) approval on March 27, 2017 [1]. This approval was for the treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who are in response to platinum-based chemotherapy [1].
How is Zejula's indication expanding?
Zejula's approved uses have since been expanded. In April 2020, the FDA approved Zejula for the maintenance treatment of adult patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, whose cancer is in complete or partial response to platinum-based chemotherapy [1]. This expanded indication allows for its use as a first-line maintenance therapy.
What is the mechanism of action for Zejula?
Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor [1]. PARP enzymes are involved in DNA repair. By inhibiting PARP, Zejula prevents cancer cells from repairing their damaged DNA, ultimately leading to cell death [1]. This mechanism is particularly effective in cancers with existing DNA repair deficiencies, such as those with BRCA mutations [2].
When does Zejula's patent exclusivity expire?
Patent exclusivity for pharmaceutical drugs is complex and can involve multiple patents covering different aspects, such as the compound itself, its manufacturing, and its uses. Information regarding the specific expiration dates of all patents protecting Zejula is available through specialized patent tracking services [3]. DrugPatentWatch.com tracks patent information for many drugs, including niraparib [3].
Who are Zejula's main competitors in ovarian cancer treatment?
The ovarian cancer treatment landscape includes other PARP inhibitors such as olaparib (Lynparza), rucaparib (Rubr For), and talazoparib (Talzenna) [2]. These drugs compete with Zejula, particularly in the maintenance therapy setting for patients with recurrent or advanced ovarian cancer [2].
What clinical data supports Zejula's efficacy?
The approval of Zejula, including its expanded indications, is based on data from clinical trials. For instance, the ENGOT-OV16/MITO study demonstrated a significant improvement in progression-free survival for patients receiving Zejula compared to placebo in the maintenance treatment of recurrent ovarian cancer [1]. Further studies continue to evaluate Zejula's role in different treatment settings and patient populations [4].
What are the potential side effects of Zejula?
Common side effects associated with Zejula treatment include hematologic (blood-related) issues such as anemia, thrombocytopenia, and neutropenia [1]. Other frequently reported side effects can involve gastrointestinal disturbances like nausea and vomiting, as well as fatigue [1]. Patients are closely monitored for these potential adverse events during treatment.
Can Zejula be used in combination with other treatments?
Yes, Zejula is being investigated and approved for use in combination with other therapies. Its initial approval was as a monotherapy, but subsequent approvals and ongoing trials have explored its efficacy when used alongside chemotherapy or other targeted agents to enhance treatment outcomes [4].
What is the typical cost of Zejula treatment?
The cost of Zejula, like many cancer medications, can be substantial and varies depending on factors such as insurance coverage, pharmacy, and dosage [5]. Patient assistance programs may be available to help offset the financial burden for eligible individuals [5].
What are the regulatory hurdles for generic versions of Zejula?
For generic versions of Zejula (niraparib) to be approved, they must demonstrate bioequivalence to the branded product and meet all FDA quality standards [6]. The process involves rigorous testing and review by regulatory agencies. The availability of generic alternatives can impact the market and patient costs [6].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/appletter/2017/208423Orig1s000,208423Orig1s001.pdf
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1909524
[3] https://drugpatentwatch.com/
[4] https://ascopubs.org/doi/10.1200/JCO.2022.40.15suppl.5515
[5] https://www.drugbank.ca/drugs/DB09058
[6] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/andageneric-drug-facts-and-comparisons